1. Home
  2. TWIN vs CBIO Comparison

TWIN vs CBIO Comparison

Compare TWIN & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TWIN
  • CBIO
  • Stock Information
  • Founded
  • TWIN 1918
  • CBIO 2003
  • Country
  • TWIN United States
  • CBIO United States
  • Employees
  • TWIN N/A
  • CBIO N/A
  • Industry
  • TWIN Industrial Machinery/Components
  • CBIO
  • Sector
  • TWIN Industrials
  • CBIO
  • Exchange
  • TWIN Nasdaq
  • CBIO Nasdaq
  • Market Cap
  • TWIN 224.5M
  • CBIO 208.8M
  • IPO Year
  • TWIN N/A
  • CBIO N/A
  • Fundamental
  • Price
  • TWIN $16.90
  • CBIO $13.00
  • Analyst Decision
  • TWIN Strong Buy
  • CBIO Strong Buy
  • Analyst Count
  • TWIN 1
  • CBIO 5
  • Target Price
  • TWIN $12.00
  • CBIO $25.60
  • AVG Volume (30 Days)
  • TWIN 38.7K
  • CBIO 106.2K
  • Earning Date
  • TWIN 11-05-2025
  • CBIO 11-06-2025
  • Dividend Yield
  • TWIN 0.94%
  • CBIO N/A
  • EPS Growth
  • TWIN N/A
  • CBIO N/A
  • EPS
  • TWIN 0.02
  • CBIO N/A
  • Revenue
  • TWIN $347,837,000.00
  • CBIO N/A
  • Revenue This Year
  • TWIN $10.79
  • CBIO N/A
  • Revenue Next Year
  • TWIN $8.43
  • CBIO N/A
  • P/E Ratio
  • TWIN $917.39
  • CBIO N/A
  • Revenue Growth
  • TWIN 14.24
  • CBIO N/A
  • 52 Week Low
  • TWIN $6.16
  • CBIO $9.81
  • 52 Week High
  • TWIN $17.08
  • CBIO $21.40
  • Technical
  • Relative Strength Index (RSI)
  • TWIN 69.85
  • CBIO 57.56
  • Support Level
  • TWIN $14.68
  • CBIO $12.00
  • Resistance Level
  • TWIN $16.22
  • CBIO $12.84
  • Average True Range (ATR)
  • TWIN 0.66
  • CBIO 0.58
  • MACD
  • TWIN -0.02
  • CBIO 0.07
  • Stochastic Oscillator
  • TWIN 88.52
  • CBIO 82.51

About TWIN Twin Disc Incorporated

Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: